Autistic Disorder: Clinical Trials

66 trials for Autistic Disorder, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

50 completed, 6 terminated, 3 not yet recruiting, 3 recruiting. 66 Phase 3, 18 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 366Completed 50, Terminated 6, Not yet recruiting 3, Recruiting 3, Unknown 2, Active not recruiting 1, Withdrawn 1
Phase 218Completed 12, Not yet recruiting 2, Recruiting 1, Terminated 1, Unknown 1, Withdrawn 1

Follow Autistic Disorder: new trials by email Literature Review of Autistic Disorder trials Research Report on Autistic Disorder

Trials (filtered) newest first · largest first

All 66 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Investigate the Effects and Safety of Codabakalner for the Treatment of FXS in Male Participants and Adult Participants With ADS
Codabakalner, Placebo - Fragile X Syndrome (FXS), Autism Spectrum Disorder (ASD)
Phase 2 / Phase 3Not yet recruitingSpinogenix1202026-12-012026-10-09
NTI164 in Autism Spectrum Disorder
NTI164, Placebo - Autism, Autism Spectrum Disorder
Phase 3Not yet recruitingFenix Innovation Group2002026-09-302026-09-30
Double-Blind Trial of Everolimus for Improving Social Abilities in PTEN Germline Mutations
Everolimus blinded oral capsules, Placebo - Cowden's Disease, Cowden's Syndrome
Phase 2 / Phase 3Not yet recruitingBoston Children's Hospital602026-09-012026-06-04
A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
KarXT, KarX-EC - Schizophrenia, Autism-Related Irritability
Phase 3RecruitingKaruna Therapeutics, Inc., a Bristol Myers Squibb company4002026-04-072026-11-06
Amitriptyline for Repetitive Behaviors in Autism Spectrum Disorders
amitriptyline - Autism Spectrum Disorder, Repetitive Compulsive Behavior
Phase 3TerminatedUniversity of Missouri, Kansas City12023-11-012025-05-30
Role of the Gut Vascular Barrier and Microbiota in Autism Spectrum Disorders
PostbiotiX Comfort®, Control - Autism, Autism Disorder
Phase 2 / Phase 3RecruitingFondazione I.R.C.C.S. Istituto Neurologico Carlo Besta902023-03-212026-03-04
Effect of Lithium in Patients With Autism Spectrum Disorder and Phelan-McDermid Syndrome (SHANK3 Haploinsufficiency)
Lithium Carbonate, Placebo - Autism Spectrum Disorder
Phase 3CompletedAssistance Publique - Hôpitaux de Paris222022-02-212025-10-02
Role of Bumetanide in Treatment of Autism
Bumetanide, Placebo - Autism
Phase 3RecruitingSherief Abd-Elsalam802021-01-012021-02-23
Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder for Subjects That Have Completed Participation in 331-201-00148
Brexpiprazole - Irritability Associated With Autism Spectrum Disorder
Phase 3CompletedOtsuka Pharmaceutical Development & Commercialization, Inc.952020-01-232024-05-30
The Effects of Medical Cannabis in Children With Autistic Spectrum Disorder
Cannabis oil - Autism Spectrum Disorder
Phase 3CompletedAssaf-Harofeh Medical Center1282019-11-142024-07-31
Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder
Brexpiprazole, Placebo - Irritability Associated With Autism Spectrum Disorder (ASD)
Phase 3CompletedOtsuka Pharmaceutical Development & Commercialization, Inc.1192019-10-302025-08-28
Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions
Memantine Hydrochloride, Placebo - Autism, Autism Spectrum Disorder
Phase 3TerminatedMassachusetts General Hospital252018-11-132026-02-25
Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Autistic Disorder
Aripiprazole Oral Solution, Placebo Oral Solution - Autistic Disorder
Phase 3CompletedOtsuka Beijing Research Institute1112018-04-092020-12-29
Intranasal Vasopressin Treatment in Children With Autism
Vasopressin (USP) Injectable Solution [Vasostrict], Placebo - Autism, Autism Spectrum Disorder
Phase 2 / Phase 3CompletedStanford University1572018-02-202026-06-04
Open Label of Clinical Trial of Sulforaphane in Children With Autism
Sulforaphane - Autism
Phase 3CompletedUniversity of California, San Francisco212016-01-012019-03-06
An Open Label Study of CM-AT for the Treatment of Children With Autism
CM-AT - Autism
Phase 3Active not recruitingCuremark4052015-10-012026-03-18
Cortical Metrics in Intervention Trials With Autism Spectrum Disorders
Dextromethophan - Autism Spectrum Disorders
Phase 2 / Phase 3WithdrawnDuke University2015-08-012016-08-25
Oxytocin in Adolescents With Autism Spectrum Disorders
OCYTOCINA - SPRAY NASAL - Autism Spectrum Disorder
Phase 2 / Phase 3TerminatedUniversity of Sao Paulo General Hospital302015-06-012019-10-28
A Trial of CM-AT in Children With Autism With All Levels of FCT (The Blum Study)
CM-AT, PLACEBO - Autism
Phase 3CompletedCuremark1902015-05-132023-05-24
Testing a Novel Speech Intervention in Minimally Verbal Children With Autism Spectrum Disorder (ASD)
Auditory-Motor Mapping Training, Speech-Repetition Therapy - Autism
Phase 2 / Phase 3CompletedBeth Israel Deaconess Medical Center142014-11-012020-05-19

Showing 20 of 66. Sign in to see all of them.

Narrower conditions

Autism Spectrum Disorder (21)  ·  Child Development Disorders, Pervasive (5)  ·  Asperger Syndrome (4)  ·  Attention Deficit Disorder with Hyperactivity (2)  ·  Behavioral Symptoms (2)  ·  Marijuana Abuse (2)  ·  Problem Behavior (2)  ·  Schizophrenia (2)  ·  Aggression (1)  ·  Anxiety Disorders (1)  ·  Anxiety, Separation (1)  ·  Bipolar Disorder (1)  ·  Communication (1)  ·  Developmental Disabilities (1)

Broader conditions

Mental Disorders (66)  ·  Neurodevelopmental Disorders (66)  ·  Child Development Disorders, Pervasive (61)  ·  Autism Spectrum Disorder (45)  ·  Behavior (6)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (4)  ·  Genetic Diseases, Inborn (4)  ·  Heredodegenerative Disorders, Nervous System (3)  ·  Nervous System Diseases (3)  ·  Neurobehavioral Manifestations (3)  ·  Neurologic Manifestations (3)  ·  Attention Deficit and Disruptive Behavior Disorders (2)  ·  Behavioral Symptoms (2)  ·  Chemically-Induced Disorders (2)  ·  Child Behavior (2)

Interventions

Aripiprazole (7)  ·  Risperidone (4)  ·  Cycloserine (3)  ·  Secretin (3)  ·  Bumetanide (2)  ·  Everolimus (2)  ·  Fluoxetine (2)  ·  Lurasidone Hydrochloride (2)  ·  Methylphenidate (2)  ·  Sugars (2)  ·  Vitamin B 12 (2)  ·  brexpiprazole (2)  ·  mecobalamin (2)  ·  Acupuncture Therapy (1)  ·  Amitriptyline (1)

Sponsors

University of California, San Francisco (6)  ·  Otsuka Pharmaceutical Development & Commercialization, Inc. (5)  ·  Curemark (4)  ·  Indiana University (4)  ·  The University of Hong Kong (4)  ·  Massachusetts General Hospital (3)  ·  Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (2)  ·  Neuropharm (2)  ·  Otsuka Pharmaceutical Co., Ltd. (2)  ·  Repligen Corporation (2)  ·  Sumitomo Pharma America, Inc. (2)  ·  Assaf-Harofeh Medical Center (1)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  Beth Israel Deaconess Medical Center (1)  ·  Boston Children's Hospital (1)

Countries

United States (43)  ·  France (4)  ·  Hong Kong (4)  ·  Japan (4)  ·  Australia (2)  ·  Canada (2)  ·  Hungary (2)  ·  Mexico (2)  ·  Poland (2)  ·  Puerto Rico (2)  ·  Romania (2)  ·  Spain (2)  ·  Brazil (1)  ·  Bulgaria (1)  ·  China (1)

Top investigators

Wong Virginia (4)  ·  Christopher J. McDougle, MD (3)  ·  Robert Hendren, DO (3)  ·  Robert L Hendren, DO (3)  ·  Deborah Pearson, PhD (2)  ·  Abeer Salamah, Dr (1)  ·  Alan Unis, MD (1)  ·  Antonio Y. Hardan, M.D. (1)  ·  Benedetto Vitiello, NIMH Coordinator (1)  ·  Christopher J McDougle (1)  ·  Christopher J. McDougle, M.D. (1)  ·  Craig A. Erickson, M.D. (1)  ·  David Dunn, MD (1)

Results publications

PMID 37811711, PMID 21731831, PMID 24138011, PMID 33583058, PMID 38032645, PMID 15492353, PMID 20973712, PMID 21663425, PMID 21813076, PMID 21818676, PMID 23233021, PMID 23357440, PMID 25878901, PMID 26746121, PMID 26770664, PMID 26802979, PMID 26889605, PMID 28138381, PMID 28941259, PMID 29854372, PMID 31217257, PMID 31267292, PMID 34324397, PMID 35241779, PMID 36006807, PMID 37267443

NIH funding

2018 (1), 2025 (1), K08MH001516 (1), K23MH068627 (1), P01HD035465 (1), P01HD035468 (1), R01HD091972 (1), R01MH072263 (1), R01MH072961 (1), R01MH073524 (1), R01MH077600 (1), R21MH080026 (1), U01NS061264 (1)